A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Phase of Trial: Phase III
Latest Information Update: 13 Dec 2017
At a glance
- Drugs Margetuximab (Primary) ; Capecitabine; Eribulin; Gemcitabine; Trastuzumab; Vinorelbine
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms SOPHIA
- Sponsors MacroGenics
- 08 Nov 2017 According to a company media release, MacroGenics believes it is on track to complete and announce the results of an interim futility analysis by year-end 2017 or early 2018.
- 22 Jun 2017 Planned End Date changed from 1 May 2018 to 1 Mar 2021.
- 22 Jun 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Mar 2020.